Gregory C. Critchfield
Chairman, President, & CEO at Sera Prognostics
Dr. Critchfield was appointed as Sera’s CEO in November 2011. Before joining Sera, Dr. Critchfield was president of Myriad Genetics Laboratories from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Myriad, he served as senior vice president/chief medical and science officer at Corning Clinical Laboratories/Quest Diagnostics. Dr. Critchfield has served on the boards of Saladax Biomedical, BioTrove, Biocius, Integrated Diagnostics, Nodality, Metamark Genetics, Lantos Technologies, Epic Sciences, and Condor Therapeutics. He holds a B.S. in Microbiology from BYU, an M.D. from the University of Utah College of Medicine, and an M.S. in Biophysical Sciences from the University of Minnesota.
Chairman, President, & CEO